The patterns of in vitro antimicrobial susceptibility and resistance of bacterial keratitis isolates in Glasgow, United Kingdom

Clinical and Experimental Optometry

Volumn 93, Issue 5, 2010, Pages 354-359

  Amer Awan, Muhammad ^a   Reeks, Gordon ^a   Rahman, Mamun Q ^a   Butcher, Ian ^b   Ramaesh, Kanna ^a  

^a Tennent Institute of Ophthalmology   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

Antibiotics; Cefuroxime; Ciprofloxacin; Corneal ulcer; Gentamicin; In vitro susceptibility; Resistance

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; ISOLATION AND PURIFICATION; KERATITIS; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; RETROSPECTIVE STUDY;

BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; KERATITIS; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES;

EID: 77956134400     PISSN: 08164622     EISSN: 14440938     Source Type: Journal    
DOI: 10.1111/j.1444-0938.2010.00511.x     Document Type: Article

References (19)

1. Chalita MR, Höfling-Lima AL, Paranhos A, Schor P, Belfort R. Shifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years. Am J Ophthalmol 2004, 137:43-45.
2. Jensen HG, Felix C. In vitro antibiotic susceptibilities of ocular isolates in North and South America. Cornea 1998, 17:79-87.
3. Bowe BE, Snyder JW, Eiferman RA. An in vitro study of the potency and stability of fortified ophthalmic antibiotic preparations. Am J Ophthalmol 1991, 111:686-689.
4. Davison CR, Tuft SJ, Dart JK. Conjunctival necrosis after administration of topical fortified aminoglycosides. Am J Ophthalmol 1991, 111:690-693.
5. A double-masked, randomized, controlled trial with conventional dual therapy. The Ofloxacin Study Group. Ophthalmology 1997, 104:1902-1909. Ofloxacin monotherapy for the primary treatment of microbial keratitis
6. Hyndiuk RA, Eiferman RA, Caldwell DR, Rosenwasser GO, Santos CI, Katz HR, Badrinath SS. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology 1996, 103:1854-1863.
7. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology 1999, 106:1313-1318.
8. Chaudhry NA, Flynn HW, Murray TG, Tabandeh H, Mello MO, Miller D. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol 1999, 128:509-510.
9. Fong CF, Hu FR, Tseng CH, Wang IJ, Chen WL, Hou YC. Antibiotic susceptibility of bacterial isolates from bacterial keratitis cases in a university hospital in Taiwan. Am J Ophthalmol 2007, 144:682-689.
10. Tuft SJ, Matheson M. In vitro antibiotic resistance in bacterial keratitis in London. Br J Ophthalmol 2000, 84:687-691.
11. Smitha S, Lalitha P, Prajna VN, Srinivasan M. Susceptibility trends of Pseudomonas species from corneal ulcers. Indian J Med Microbiol 2005, 23:168-171.
12. Kunimoto DY, Sharma S, Garg P, Rao GN. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Emerging resistance. Ophthalmology 1999, 106:80-85.
13. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology 2000, 107:1497-1502.
14. Marangon FB, Miller D, Muallem MS, Romano AC, Alfonso EC. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol 2004, 137:453-458.
15. Ly CN, Pham JN, Badenoch PR, Bell SM, Hawkins G, Rafferty DL, McClellan KA. Bacteria commonly isolated from keratitis specimens retain antibiotic susceptibility to fluoroquinolones and gentamicin plus cephalothin. Clin Experiment Ophthalmol 2006, 34:44-50.
16. Asbell PA, Sahm DF, Shaw M, Draghi DC, Brown NP. Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005. J Cataract Refract Surg 2008, 34:814-818.
17. Garg P, Sharma S, Rao GN. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology 1999, 106:1319-1323.
18. Stroman DW, Dajcs JJ, Cupp GA, Schlech BA. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol 2005, 50:16-31.
19. Gad GF, el-Domany RA, Ashour HM. Antimicrobial susceptibility profile of Pseudomonas aeruginosa isolates in Egypt. J Urol 2008, 180:176-181.